Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Chinese CRO WuXi PharmaTech is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons.
Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.
Parexel International, in the midst of sweeping cost cuts, said it has further integrated technology into its drug development services, creating a data-informed process designed to speed up timelines and save money.
PRA Health Sciences is moving into a bigger space in Singapore, consolidating its operations there and looking to boost its share of the growing market for clinical research in Asia.
Quintiles has contributed some open-source code to improve Apple's ResearchKit project, a platform designed to help physicians and scientists gather medical data from millions of patients.
PPD hired a general manager to help grow its Japan-focused joint venture with Shin Nippon Biomedical Laboratories, snagging a Parexel International veteran as it works to expand its presence in a growing market for clinical development services.
Eli Lilly is partnering with CRO WuXi PharmaTech to develop a cholesterol-lowering pill in China, relying on local expertise in hopes of tapping a growing market.
BioDuro, once a division of PDD, has merged with contract manufacturer Formex, expanding its production capabilities in the U.S. while maintaining its research presence in China.
Quintiles founder Dennis Gillings is set to vacate his chairmanship at the end of 2015, ending a 33-year tenure at the top that saw the North Carolina company grow into the world's biggest CRO.
German contract researcher Evotec grew its revenue by 50% in the first 9 months of 2015, executing its hybrid model and expanding its list of Big Pharma partners.